Charles River Laboratories
Logotype for Charles River Laboratories International Inc

Charles River Laboratories (CRL) investor relations material

Charles River Laboratories Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Charles River Laboratories International Inc
Jefferies Global Healthcare Conference summary17 Nov, 2026

Strategic framework and efficiency

  • CEO introduced Pathway to Purpose, focused on modernization, portfolio refinement and client centricity to support competitiveness over the next 3 years, 5 years and beyond.

  • Create the Future targets $300M in cost savings over the next 3 years, following $300M taken out over the prior 3 years; expected margin improvement is ~75 bps over the next few years.

  • Modernization aims to make processes more scalable, automated and digital; an automated Microbial Solutions production line increased capacity 14%.

  • Apollo Orchestrate will digitize Biologics Testing workflows from sample submission through lab work and reporting, including data organization and AI use.

Portfolio and client relationships

  • Divested European early discovery assets and the CDMO business together with cell supply; acquired a non-human primate facility to integrate supply and support timely critical safety studies.

  • PathoQuest acquisition adds NAMs technology intended to replace in vivo testing in Biologics Testing and cell-bank characterization, reducing a normal 20-week process by 40%.

  • Signed a primary strategic partnership with a top-10 pharmaceutical company; leadership cited stronger client access and reliable service as priorities for long-term shareholder value.

Demand, pricing and growth outlook

  • Demand improved across biotech and global biopharma; proposal rates rose high-single to high-double digits YoY for five consecutive months, while book-to-bill gains spanned both client segments.

  • Early-stage funding and company formation remain areas to monitor; biotech funding was lower in Q3 but appeared stable again in Q4.

  • Pricing increases are beginning after strategic discounting during 2024-25; capture rates remained up, but revenue realization may take a few quarters as lower-priced backlog is worked through.

  • DSA long-range growth target is 5%-7%, based on visible demand and client pipelines; AI-driven demand and further pricing could add upside, while biotech funding remains a key risk to the range.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Charles River Laboratories earnings date

Logotype for Charles River Laboratories International Inc
Q4 202617 Feb, 2027
Charles River Laboratories
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Charles River Laboratories earnings date

Logotype for Charles River Laboratories International Inc
Q4 202617 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Charles River Laboratories International, Inc. is a concract research organization providing drug discovery, non-clinical development and safety testing services in the United States, Europe, Canada and the Asia Pacific regions. The Company provides research models and related services to support clients from target identification through non-clinical development. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support.